Molar, Third Surgery, Oral
Conditions
Interventions
This is a randomized, double-blind, split-mouth, phase 4, within-person crossover clinical study. Selected individuals will be randomized into 2 groups (n=30 teeth per group), considering the split-mo
however, no radiation will be emitted to the target. The volunteers and the surgeon/researchers, who will be involved in the analyses and interpretations, will not know which group the participant bel
Sponsors
Faculdade de Odontologia de Piracicaba da Universidade Estadual de Campinas
Faculdade de Odontologia de Piracicaba da Universidade Estadual de Campinas
Eligibility
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Patients in good systemic and local health for the procedures; Patients between 18 and 35 years of age; Both sexes; Indication for extraction of third molars (teeth 38 or 48), with at least two-thirds of the root formed, according to the radiographic evaluation, thus belonging to Pell & Gregory classification I or II and position A or B (Pell GJ & Gregory GT, 1933)
Exclusion criteria
Exclusion criteria: Patients with mandibular third molars in positions 3 and C according to the Pell & Gregory classification; Presence of any local manifestations in the area of ??interest that may contraindicate the surgical procedure, such as: pericoronitis, odontogenic cysts and tumors associated or not with the third molar, trauma in the region, or any symptoms that indicate the presence of infection; Patients who smoke or have any type of systemic disease (of any organ system), such as diabetes, systemic arterial hypertension, hyperthyroidism, osteoporosis, or gastrointestinal diseases that compromise the outcome of the surgery; Patients who are intolerant to other materials that will be used in the research, such as 2% chlorhexidine alcohol solution, 0.12% chlorhexidine digluconate solution, and 2% mepivacaine hydrochloride solution with 1:100,000 epinephrine; Female patients who are menstruating, pregnant, or breastfeeding during the surgical procedure; Patients with abnormal sleep patterns, who slept less than 5 hours the night before, or who are taking medications to control psychiatric illnesses, corticosteroids, estrogens, and androgens; Patients who have used anti-inflammatory drugs within 30 days prior to the surgical procedure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To clinically compare the effectiveness of the protocol in controlling postoperative symptoms (pain, edema, maximum mouth opening and quality of life) | — |
Secondary
| Measure | Time frame |
|---|---|
| Analyze blood biochemistry through inflammatory markers (IL-1ß, IL-6, IL-10, C-reactive protein, TNF-a and prostaglandin E2), oxidizing substance (superoxide dismutase enzyme) and vasoactive substance (nitric oxide). | — |
Countries
BR
Contacts
Public ContactMileni Souza
Faculdade de Odontologia de Piracicaba da Universidade Estadual de Campinas
Outcome results
None listed